8 research outputs found
Nocturnal Hypoxemia and CT Determined Pulmonary Artery Enlargement in Smokers
Background: Pulmonary artery enlargement (PAE) detected using chest computed tomography (CT) is associated with poor outcomes in chronic obstructive pulmonary disease (COPD). It is unknown whether nocturnal hypoxemia occurring in smokers, with or without COPD, obstructive sleep apnoea (OSA) or their overlap, may be associated with PAE assessed by chest CT.
Methods: We analysed data from two prospective cohort studies that enrolled 284 smokers in lung cancer screening programs and completing baseline home sleep studies and chest CT scans. Main pulmonary artery diameter (PAD) and the ratio of the PAD to that of the aorta (PA:Ao ratio) were measured. PAE was defined as a PAD >= 29 mm in men and >= 27 mm in women or as a PA:Ao ratio > 0.9. We evaluated the association of PAE with baseline characteristics using multivariate logistic models.
Results: PAE prevalence was 27% as defined by PAD measurements and 11.6% by the PA:Ao ratio. A body mass index >= 30 kg/m(2) (OR 2.01; 95%CI 1.06-3.78), lower % predicted of forced expiratory volume in one second (FEV1) (OR 1.03; 95%CI 1.02-1.05) and higher % of sleep time with O-2 saturation < 90% (T90) (OR 1.02; 95%CI 1.00-1.03), were associated with PAE as determined by PAD. However, only T90 remained significantly associated with PAE as defined by the PA:Ao ratio (OR 1.02; 95%CI 1.01-1.03). In the subset group without OSA, only T90 remains associated with PAE, whether defined by PAD measurement (OR 1.02; 95%CI 1.01-1.03) or PA:Ao ratio (OR 1.04; 95%CI 1.01-1.07).
Conclusions: In smokers with or without COPD, nocturnal hypoxemia was associated with PAE independently of OSA coexistence
Exploring the Association Between Emphysema Phenotypes and Low Bone Mineral Density in Smokers with and without COPD
Rationale: Emphysema and osteoporosis are tobacco-related diseases. Many studies have
shown that emphysema is a strong and independent predictor of low bone mineral density
(BMD) in smokers; however, none of them explored its association with different emphysema subtypes.
Objective: To explore the association between the different emphysema subtypes and the
presence of low bone mineral density in a population of active or former smokers with and
without chronic obstructive pulmonary disease (COPD).
Methods: One hundred and fifty-three active and former smokers from a pulmonary clinic
completed clinical questionnaires, pulmonary function tests, a low-dose chest computed
tomography (LDCT) and a dual-energy absorptiometry (DXA) scans. Subjects were classified as having normal BMD or low BMD (osteopenia or osteoporosis). Emphysema was
classified visually for its subtype and severity. Logistic regression analysis explored the
relationship between the different emphysema subtypes and the presence of low BMD
adjusting for other important factors.
Results: Seventy-five percent of the patients had low BMD (78 had osteopenia and 37 had
osteoporosis). Emphysema was more frequent (66.1 vs 26.3%, p=<0.001) and severe in those
with low BMD. Multivariable analysis adjusting for other significant cofactors (age, sex,
FEV1, and severity of emphysema) showed that BMI (OR=0.91, 95% CI: 0.76–0.92) and
centrilobular emphysema (OR=26.19, 95% CI: 1.71 to 399.44) were associated with low
BMD.
Conclusion: Low BMD is highly prevalent in current and former smokers. BMI and
centrilobular emphysema are strong and independent predictors of its presence, which
suggests that they should be considered when evaluating smokers at risk for low BMD
Exploring the Association Between Emphysema Phenotypes and Low Bone Mineral Density in Smokers with and without COPD
Rationale: Emphysema and osteoporosis are tobacco-related diseases. Many studies have
shown that emphysema is a strong and independent predictor of low bone mineral density
(BMD) in smokers; however, none of them explored its association with different emphysema subtypes.
Objective: To explore the association between the different emphysema subtypes and the
presence of low bone mineral density in a population of active or former smokers with and
without chronic obstructive pulmonary disease (COPD).
Methods: One hundred and fifty-three active and former smokers from a pulmonary clinic
completed clinical questionnaires, pulmonary function tests, a low-dose chest computed
tomography (LDCT) and a dual-energy absorptiometry (DXA) scans. Subjects were classified as having normal BMD or low BMD (osteopenia or osteoporosis). Emphysema was
classified visually for its subtype and severity. Logistic regression analysis explored the
relationship between the different emphysema subtypes and the presence of low BMD
adjusting for other important factors.
Results: Seventy-five percent of the patients had low BMD (78 had osteopenia and 37 had
osteoporosis). Emphysema was more frequent (66.1 vs 26.3%, p=<0.001) and severe in those
with low BMD. Multivariable analysis adjusting for other significant cofactors (age, sex,
FEV1, and severity of emphysema) showed that BMI (OR=0.91, 95% CI: 0.76–0.92) and
centrilobular emphysema (OR=26.19, 95% CI: 1.71 to 399.44) were associated with low
BMD.
Conclusion: Low BMD is highly prevalent in current and former smokers. BMI and
centrilobular emphysema are strong and independent predictors of its presence, which
suggests that they should be considered when evaluating smokers at risk for low BMD
Immunological Biomarkers of Fatal COVID-19: A Study of 868 Patients
Information on the immunopathobiology of coronavirus disease 2019 (COVID-19) is rapidly increasing; however, there remains a need to identify immune features predictive of fatal outcome. This large-scale study characterized immune responses to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection using multidimensional flow cytometry, with the aim of identifying high-risk immune biomarkers. Holistic and unbiased analyses of 17 immune cell-types were conducted on 1,075 peripheral blood samples obtained from 868 COVID-19 patients and on samples from 24 patients presenting with non-SARS-CoV-2 infections and 36 healthy donors. Immune profiles of COVID-19 patients were significantly different from those of age-matched healthy donors but generally similar to those of patients with non-SARS-CoV-2 infections. Unsupervised clustering analysis revealed three immunotypes during SARS-CoV-2 infection; immunotype 1 (14% of patients) was characterized by significantly lower percentages of all immune cell-types except neutrophils and circulating plasma cells, and was significantly associated with severe disease. Reduced B-cell percentage was most strongly associated with risk of death. On multivariate analysis incorporating age and comorbidities, B-cell and non-classical monocyte percentages were independent prognostic factors for survival in training (n=513) and validation (n=355) cohorts. Therefore, reduced percentages of B-cells and non-classical monocytes are high-risk immune biomarkers for risk-stratification of COVID-19 patients
Immunological Biomarkers of Fatal COVID-19: A Study of 868 Patients
Information on the immunopathobiology of coronavirus disease 2019 (COVID-19) is rapidly increasing; however, there remains a need to identify immune features predictive of fatal outcome. This large-scale study characterized immune responses to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection using multidimensional flow cytometry, with the aim of identifying high-risk immune biomarkers. Holistic and unbiased analyses of 17 immune cell-types were conducted on 1,075 peripheral blood samples obtained from 868 COVID-19 patients and on samples from 24 patients presenting with non-SARS-CoV-2 infections and 36 healthy donors. Immune profiles of COVID-19 patients were significantly different from those of age-matched healthy donors but generally similar to those of patients with non-SARS-CoV-2 infections. Unsupervised clustering analysis revealed three immunotypes during SARS-CoV-2 infection; immunotype 1 (14% of patients) was characterized by significantly lower percentages of all immune cell-types except neutrophils and circulating plasma cells, and was significantly associated with severe disease. Reduced B-cell percentage was most strongly associated with risk of death. On multivariate analysis incorporating age and comorbidities, B-cell and non-classical monocyte percentages were independent prognostic factors for survival in training (n=513) and validation (n=355) cohorts. Therefore, reduced percentages of B-cells and non-classical monocytes are high-risk immune biomarkers for risk-stratification of COVID-19 patients